[Form 4] Mind Medicine (MindMed) Inc. Insider Trading Activity

Rhea-AI Filing Summary

Definium Therapeutics, Inc. reported that Chief Executive Officer and director Robert Barrow received an award of 320,000 restricted stock units (RSUs), each representing one common share. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026. After this grant, Barrow beneficially owns 1,098,477 common shares of Definium Therapeutics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrow Robert

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A		320,000(1)	A	$0.00	1,098,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.

	/s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Definium Therapeutics (DFTX) report for Robert Barrow?

Definium Therapeutics reported that CEO and director Robert Barrow received 320,000 restricted stock units. Each RSU represents a contingent right to one common share, increasing his beneficial ownership to 1,098,477 common shares following the reported transaction on February 3, 2026.

How many Definium Therapeutics (DFTX) shares does Robert Barrow own after this Form 4?

Following the reported RSU grant, Robert Barrow beneficially owns 1,098,477 common shares of Definium Therapeutics. This total includes the 320,000 newly awarded restricted stock units, each convertible into one common share upon vesting under the stated schedule.

What are the terms of the 320,000 RSUs granted to Definium Therapeutics (DFTX) CEO Robert Barrow?

Robert Barrow’s 320,000 RSUs each represent a contingent right to receive one common share. The RSUs vest in 16 equal quarterly installments starting June 1, 2026, conditioned on his continued service with Definium Therapeutics on each applicable vesting date.

When do Robert Barrow’s Definium Therapeutics (DFTX) RSUs begin vesting?

The RSUs granted to Robert Barrow begin vesting on June 1, 2026. Vesting occurs in 16 equal quarterly installments from that date, subject to his continuous service to Definium Therapeutics on each scheduled vesting date described in the Form 4 footnote.

What price per share applies to the 320,000 RSUs reported by Definium Therapeutics (DFTX)?

The Form 4 lists a transaction price of $0.00 per share for the 320,000 common share RSUs. This reflects the nature of restricted stock units as equity awards rather than open-market purchases, with value realized as units vest into common shares.